6 unchanged sentences
001-39083), filed with the SEC on October 16, 2019).
−Removed: Patent License Agreement between the Company and Xencor, Inc., dated March 25, 2020 (incorporated herein by reference to Exhibit 99.1 to the Company's Form 8-K (File No.
−Removed: 001-39083), filed with the SEC on June 19, 2020).
−Removed: Amendment No.
−Removed: 3 to the Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated April 1, 2020 (incorporated herein by reference to Exhibit 10.21 to the Company's Registration Statement on Form S-1 (File No.
−Removed: 333-239689), filed with the SEC on July 6, 2020).
−Removed: Preliminary Collaboration Agreement between the Company, GlaxoSmithKline Intellectual Property Development Limited and GlaxoSmithKline Biologicals SA, dated April 5, 2020 (incorporated herein by reference to Exhibit 10.53 to the Company's Registration Statement on Form S-1 (File No.
−Removed: 333-239689), filed wih the SEC on July 6, 2020).
−Removed: Definitive Collaboration Agreement between the Company and Glaxo Wellcome UK Limited and Beecham S.A., dated June 9, 2020 (incorporated herein by reference to Exhibit 10.54 to the Company's Registration Statement on Form S-1 (File No.
−Removed: 333-239689), filed with the SEC on July 6, 2020).
−Removed: Stock Purchase Agreement between the Company and Glaxo Group Limited, dated April 5, 2020 (incorported herein by reference to Exhibit 10.55 to the Company's Registration Statement on Form S-1 (File No.
−Removed: 333-239689), filed with the SEC on July 6, 2020).
−Removed: Clinical Development and Manufacturing Agreement between the Company and Biogen Inc., dated May 22, 2020 (incorporated herein by reference to Exhibit 10.56 to the Company’s Registration Statement on Form S-1 (File No.
−Removed: 333-239689), filed with the SEC on July 6, 2020).
−Removed: Binding Letter Agreement between the Company and Samsung Biologics Co., Ltd., dated April 9, 2020 (incorporated herein by reference to Exhibit 10.57 to the Company’s Registration Statement on Form S-1 (File No.
−Removed: 333-239689), filed with the SEC on July 6, 2020).
Assignment and Novation Agreement among the Company, GlaxoSmithKline Trading Services Limited and Samsung Biologics Co., Ltd., dated July 31, 2020 (incorporated herein by reference to Exhibit 99.2 to the Company’s Form 8-K (File No.
001-39083), filed with the SEC on August 7, 2020).
−Removed: Development and Manufacturing Collaboration Agreement between the Company and Wuxi Biologics (Hong Kong) Limited, dated February 25, 2020 (incorporated herein by reference to Exhibit 10.58 to the Company’s Registration Statement on Form S-1 (File No.
−Removed: 333-239689), filed with the SEC on July 6, 2020).
−Removed: Letter of Intent between the Company and Wuxi Biologics (Hong Kong) Limited, dated June 15, 2020 (incorporated herein by reference to Exhibit 10.59 to the Company’s Registration Statement on Form S-1 (File No.
−Removed: 333-239689), filed with the SEC on July 6, 2020).
Assignment and Novation Agreement among the Company, GlaxoSmithKline Trading Services Limited and WuXi Biologics (Hong Kong) Limited, dated July 29, 2020 (incorporated herein by reference to Exhibit 99.1 to the Company’s Form 8-K (File No.
001-39083), filed with the SEC on August 7, 2020).
−Removed: Amendment No.
−Removed: 3 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated May 29, 2020.
+Added: Employment Letter Agreement between the Company and Steven Rice, dated August 22, 2019.
+Added: Promotion Letter Agreement between the Company and Steven Rice, dated July 30, 2020.
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
9 unchanged sentences
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
−Removed: Certain portions of this exhibit (indicated by “[***]”) have been omitted pursuant to confidential treatment.
+Added: Indicates a management contract or compensatory plan.
The certification attached as Exhibit 32.1 accompanies this Quarterly Report on Form 10-Q pursuant to 18 U.S.C.
2 unchanged sentences
VIR BIOTECHNOLOGY, INC .
−Removed: August 11, 2020
+Added: November 10, 2020
/s/ George Scangos
2 unchanged sentences
(Principal Executive Officer)
−Removed: August 11, 2020
+Added: November 10, 2020
/s/ Howard Horn
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.